• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: AV-TEMECULA-CT ACCULINK CAROTID STENT SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

AV-TEMECULA-CT ACCULINK CAROTID STENT SYSTEM Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Intracranial Hemorrhage (1891); Stenosis (2263)
Event Date 04/01/2007
Event Type  Injury  
Event Description
This event was captured based upon review of the article, ct perfusion-guided versus time-guided mechanical recanalization in acute ischemic stroke patients.It was reported that a retrospective study was performed to compare the safety and efficacy of ct [computed tomography] perfusion (ctp)-guided to time-guided mechanical recanalization in acute ischemic stroke (ais) patients.Patients from the stroke database of this site were reviewed from (b)(6) 2007 through (b)(6) 2012, with 132 patients, 94 undergoing ctp-guided and 38 undergoing time-guided mechanical recanalization recruited to the study.The rate of partial-to-complete recanalization did not differ between the ctp and the non-ctp group (78.7% vs.81.6%, respectively).Ich [intracranial hemorrhage] occurred respectively in 18.1% in the ctp group versus 31.6% in the non-ctp group.The overall in-hospital mortality rate was significantly lower in the ctp group (15.9% vs.36.8%).The study conclusions were that ctp-based patient selection was associated with lower ich and mortality rates.Favorable outcomes, however, did not differ between the 2 groups.These results may suggest a possible benefit in terms of in-hospital mortality with ctp-guided triage of ais [acute ischemic stroke] patients for endovascular treatment.This report represents the 75 potential clinical outcomes of restenosis with treatment and intracranial hemorrhage related to the acculink stent.
 
Manufacturer Narrative
(b)(4).Mean age for ctp group was 66.5, for non-ctp group was 63.5.Female gender for ctp group was 58 patients, for non-ctp group was 19 patients.Male gender for ctp group was 36 patients, for non-ctp group was 19 patients.Date of event is estimated as (b)(6) 2007.Patients reviewed underwent mechanical thrombectomy between (b)(6) 2007 and (b)(6) 2012.Mean national institutes of health stroke scale (nihss) for ctp group was 16.0, for non-ctp group was 17.1.Iv-tpa for ctp group was 44, for non-ctp group was 15.Site of occlusion: middle cerebral artery: ctp patients was 59, non-ctp patients was 20.Internal cerebral artery: ctp patients was 15, non-ctp patients was 10.Basilar artery: ctp patients was 7, non-ctp patients was 8.Multiple occlusions: ctp patients was 13, non-ctp patients was 0.Date of implant is estimated as (b)(6) 2007.It is indicated that the device is not returning for evaluation; therefore, a failure analysis of the complaint device could not be completed.Reviews of the lot history record and complaint history could not be conducted because the lot number was not provided.This incident was reported with the absence of any device malfunction.As a result, a similar incident query is not required as the complaint details and the lot history record review did not reveal a potential device relationship to the reported incident.The reported patient effects of hemorrhage and restenosis are listed in the rx acculink, domestic, instructions for use.Although a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined, there is no indication of a product quality deficiency with respect to manufacturing, design or labeling.Based on the information reviewed, there is no indication of a product deficiency.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ACCULINK CAROTID STENT SYSTEM
Type of Device
CAROTID STENT SYSTEM
Manufacturer (Section D)
AV-TEMECULA-CT
abbott vascular
26531 ynez road
temecula CA 92591 462
Manufacturer (Section G)
ABBOTT VASCULAR, TEMECULA, CA USA REG# 2024168
abbott vascular
26531 ynez road
temecula CA 92591 462
Manufacturer Contact
connie speck
abbott vascular
26531 ynez road
temecula, CA 92591-4628
9519143996
MDR Report Key3680343
MDR Text Key4298919
Report Number2024168-2014-01559
Device Sequence Number1
Product Code NIM
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P040012
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature
Reporter Occupation Health Professional
Remedial Action Other
Type of Report Initial
Report Date 01/15/2014
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/14/2014
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received02/24/2014
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-